Cytarabine-induced non-cardiogenic pulmonary edema
10.3760/cma.j.cn114015-20230724-00548
- VernacularTitle:阿糖胞苷致非心源性肺水肿
- Author:
Hu DU
1
;
Xiaodong CHEN
;
Xiao HU
;
Wenqi HUANG
Author Information
1. 重庆医科大学附属第二医院重症医学科，重庆 400010
- Publication Type:Journal Article
- Keywords:
Leukemia, myeloid;
Cytarabine;
Pulmonary edema;
Death
- From:
Adverse Drug Reactions Journal
2024;26(3):186-188
- CountryChina
- Language:Chinese
-
Abstract:
A 30-year-old female patient with acute myeloid leukemia received chemotherapy with IA regimen of cytarabine (200 mg/m 2 once daily by IV infusion, 7 days in total) and idarubicin (10 mg/m 2 once daily by IV infusion, 3 days in total). On the 5th day of treatments, the patient developed dyspnea, with breath rate 35 times/min and finger pulse oxygen saturation 92%. She was treated with high flow oxygen inhalation, but the patient′s dyspnea was aggravated at night, with heart rate 160 times/min and breath rate 50 times/min; the finger pulse oxygen saturation decreased to 50%. Lung CT examination next day showed bilateral alveolar pulmonary edema with interstitial pulmonary edema, which was considered as non- cardiogenic pulmonary edema caused by cytarabine. Chemotherapy drugs were stopped and glucocorticoids, diuresis, lung protective ventilation, prone position ventilation, and other treatments were given, but the patient′s relevant symptoms were not improved. Ten days later, the patient developed secondary pneumothorax and died due to respiratory failure.
